← Scoopfeeds — Intelligent news, curated.
Elutia reports Q1 results, expects FDA clearance for NXT-41
business

Elutia reports Q1 results, expects FDA clearance for NXT-41

Investing.com · May 14, 2026, 8:53 PM · Also reported by 4 other sources

Elutia reports Q1 results, expects FDA clearance for NXT-41

Read full story on Investing.com → More top stories

Also covered by

Yahoo Finance Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026 Yahoo Finance DarioHealth Reports Q1 2026 Results: Full Earnings Call Transcript Yahoo Finance Westwater Resources Reports Q1 2026 Results: Full Earnings Call Transcript Yahoo Finance Evolution Petroleum Reports Q3 2026 Results: Full Earnings Call Transcript

More in business

Investing.com
Form 144 MOLINA HEALTHCARE For: 14 May
Investing.com
Form 144 CATERPILLAR INC. For: 14 May
Investing.com
Form 144 ALKAMI TECHNOLOGY For: 14 May
Investing.com
Peru’s central bank holds benchmark interest rate at 4.25%
Investing.com
Earnings call transcript: Nu Holdings misses Q1 2026 EPS, stock steady
Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop